China SXT Pharmaceuticals Inc (SXTC) Stock Analysis

Verdict: AVOID

Relentless dilutive share issuances and collapsing sales (-34.6% YoY) destroy shareholder value despite nominal cash balance reserves.

Investment score: 10/100

Analysis as of

Is China SXT Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis

The TradeMates model maintains a strict AVOID recommendation on China SXT Pharmaceuticals (SXTC) due to systemic shareholder dilution, crashing revenues (-34.6% YoY), and extreme operating losses (-625.9% margin).

7-factor investment score

China SXT Pharmaceuticals Inc opportunities and risks

What speaks for SXTC

What speaks against SXTC

Frequently asked questions about China SXT Pharmaceuticals Inc (SXTC)

Is SXTC stock a good investment?

The TradeMates model rates China SXT Pharmaceuticals Inc as AVOID with an investment score of 10/100. The TradeMates model maintains a strict AVOID recommendation on China SXT Pharmaceuticals (SXTC) due to systemic shareholder dilution, crashing revenues (-34.6% YoY), and extreme operating losses (-625.9% margin). This is algorithmic model output, not personal investment advice.

Is SXTC stock a buy?

The TradeMates model verdict for SXTC is AVOID with an investment score of 10/100. Treat this as a model signal to review, not a personal buy recommendation.